Summary
The response makes general statements about clobazam API/finished drug relationships and GMP/API supplier vetting that are not addressed in the provided FDA label excerpts; only the portion implying that clobazam is a benzodiazepine and related use is plausibly consistent, but there is insufficient on-label support for most claims.
Category Scores
Accurate Statements
Clobazam API refers to clobazam active pharmaceutical ingredient (the drug substance used by manufacturers to make finished medicines).
Not supported or contradicted by the provided FDA label excerpts (which only include opioid/CNS-depressant warnings and related counseling).
Clobazam API is not the same as the finished drug (e.g., Onfi).
Not supported or contradicted by the provided FDA label excerpts.
Finished medications containing clobazam include clobazam plus other formulation ingredients such as binders, fillers, and coatings.
Not supported or contradicted by the provided FDA label excerpts.
Clobazam is a benzodiazepine used in some countries for seizure-related conditions such as epilepsy.
The provided FDA label excerpts explicitly refer to “benzodiazepines” and include clobazam products (SYMPAZAN/ONFI) within those warnings, which supports classification as a benzodiazepine; the specific statement about “used in some countries…for epilepsy” is not addressed in the provided excerpts.
Clobazam is often used as adjunctive therapy for epilepsy.
Not supported by the provided FDA label excerpts.
Clobazam API must meet quality and safety requirements, such as GMP manufacturing and compliance with pharmacopeial specifications, before being used to produce finished products.
Not supported or contradicted by the provided FDA label excerpts.
When vetting an API supplier, certificates of analysis (CoA), impurity profiles, batch/lot traceability, GMP statements, and regulatory support documents are commonly requested.
Not supported or contradicted by the provided FDA label excerpts.
Clobazam API suppliers can include generic drug makers and API manufacturers that produce benzodiazepine active ingredients for downstream brands and generics.
Not supported or contradicted by the provided FDA label excerpts.
Clobazam API may be used in compounded products in some jurisdictions only through licensed compounding channels under applicable regulations.
Not supported or contradicted by the provided FDA label excerpts.
Rules for compounded use of clobazam API vary by country/state, including requirements for sourcing from permitted suppliers and meeting specific labeling/recordkeeping standards.
Not supported or contradicted by the provided FDA label excerpts.
Unsupported Statements
Clobazam is a benzodiazepine used in some countries for seizure-related conditions such as epilepsy.
The provided FDA label excerpts do not include an indication statement or country-specific use information; only benzodiazepine-class warnings tied to SYMPAZAN/ONFI are included.
Clobazam is often used as adjunctive therapy for epilepsy.
No indication/dosing/adjunctive-therapy information is present in the provided FDA label excerpts.
Clobazam API must meet quality and safety requirements, such as GMP manufacturing and compliance with pharmacopeial specifications, before being used to produce finished products.
Quality system/GMP/API supply requirements are not addressed in the provided FDA label excerpts.
Clobazam API may be used in compounded products in some jurisdictions only through licensed compounding channels under applicable regulations.
Compounding-specific legal/regulatory requirements are not addressed in the provided FDA label excerpts.
Rules for compounded use of clobazam API vary by country/state, including requirements for sourcing from permitted suppliers and meeting specific labeling/recordkeeping standards.
No compounding-specific jurisdictional variability is addressed in the provided FDA label excerpts.
When vetting an API supplier, certificates of analysis (CoA), impurity profiles, batch/lot traceability, GMP statements, and regulatory support documents are commonly requested.
Supplier vetting practices are not addressed in the provided FDA label excerpts.
Clobazam API suppliers can include generic drug makers and API manufacturers that produce benzodiazepine active ingredients for downstream brands and generics.
The FDA label excerpts provided do not address API supply chain composition.
Finished medications containing clobazam include clobazam plus other formulation ingredients such as binders, fillers, and coatings.
Formulation/excipients composition is not addressed in the provided FDA label excerpts.
Clobazam API refers to clobazam active pharmaceutical ingredient (the drug substance used by manufacturers to make finished medicines).
API definition is not addressed in the provided FDA label excerpts.
Clobazam API is not the same as the finished drug (e.g., Onfi).
The label excerpts do not discuss API vs finished product distinctions.
Contradictions
Important Omissions
FDA label-supported indication/dosing/administration information for clobazam (SYMPAZAN/ONFI) was not provided, limiting the ability to verify any indication-related claims (e.g., epilepsy/adjunctive therapy).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Most claims are about API supply chain, compounding, and formulation generalities not directly tied to patient dosing or specific boxed warnings; however, indication/therapy assertions are not verifiable from the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Unverifiable
Primary Issue
Most statements are not addressed in the provided FDA label excerpts, which focus on opioid/CNS-depressant warnings and related counseling; only class-level benzodiazepine references are present.
Suggested Improvement
Limit claims to what is supported by the provided label text (e.g., benzodiazepine class language and opioid/CNS-depressant warning content). If evaluating indication/dosing, supply the label sections that state the approved indications and dosing/administration.